TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

PURPOSE: This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma expressing guanylyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Yung-Jue, Takano, Toshimi, Lin, Chia-Chi, Fasanmade, Adedigbo, Yang, Huyuan, Danaee, Hadi, Asato, Takayuki, Kalebic, Thea, Wang, Hui, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912138/
https://www.ncbi.nlm.nih.gov/pubmed/28494535
http://dx.doi.org/10.4143/crt.2017.074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912138/
https://www.ncbi.nlm.nih.gov/pubmed/28494535
http://dx.doi.org/10.4143/crt.2017.074

Ejemplares similares